Tanespimycin nanoemulsion - Biogen Idec

Drug Profile

Tanespimycin nanoemulsion - Biogen Idec

Alternative Names: CNF 101; CNF 1010

Latest Information Update: 09 Oct 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biogen Idec
  • Class Antineoplastics; Benzoquinones; Cytostatic antibiotics; Macrocyclic lactams; Small molecules
  • Mechanism of Action Heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Chronic myeloid leukaemia; Solid tumours

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 17 May 2007 Discontinued - Phase-I for Chronic myeloid leukaemia in USA (IV-infusion)
  • 17 May 2007 Discontinued - Phase-I for Solid tumours in USA (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top